89 related articles for article (PubMed ID: 8311001)
21. Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junction.
Davies AR; Gossage JA; Zylstra J; Mattsson F; Lagergren J; Maisey N; Smyth EC; Cunningham D; Allum WH; Mason RC
J Clin Oncol; 2014 Sep; 32(27):2983-90. PubMed ID: 25071104
[TBL] [Abstract][Full Text] [Related]
22. Evolution of treatment strategies for adenocarcinoma of the esophagus and gastroesophageal junction.
Wright CD; Mathisen DJ; Wain JC; Grillo HC; Hilgenberg AD; Moncure AC; Carey RW; Choi NC; Daly M; Logan DL
Ann Thorac Surg; 1994 Dec; 58(6):1574-8; discussion 1578-9. PubMed ID: 7979718
[TBL] [Abstract][Full Text] [Related]
23. [Trastuzumab in combination with chemotherapy versus chemotherapy alone for first-line treatment of HER2-positive advanced gastric or gastroesophageal junction cancer: a Phase III, multi-center, randomized controlled trial, Chinese subreport].
Shen L; Xu JM; Feng FY; Jiao SC; Wang LW; Li J; Guan ZZ; Qin SK; Wang JJ; Yu SY; Wang YJ; Jin YN; Tao M; Zheng LZ; Pan LX
Zhonghua Zhong Liu Za Zhi; 2013 Apr; 35(4):295-300. PubMed ID: 23985260
[TBL] [Abstract][Full Text] [Related]
24. Phase II trial of preoperative irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for resectable locally advanced gastric and esophagogastric junction adenocarcinoma.
Rivera F; Galán M; Tabernero J; Cervantes A; Vega-Villegas ME; Gallego J; Laquente B; Rodríguez E; Carrato A; Escudero P; Massutí B; Alonso-Orduña V; Cardenal A; Sáenz A; Giralt J; Yuste AL; Antón A; Aranda E;
Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1430-6. PubMed ID: 19540072
[TBL] [Abstract][Full Text] [Related]
25. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus.
Ilson DH; Ajani J; Bhalla K; Forastiere A; Huang Y; Patel P; Martin L; Donegan J; Pazdur R; Reed C; Kelsen DP
J Clin Oncol; 1998 May; 16(5):1826-34. PubMed ID: 9586897
[TBL] [Abstract][Full Text] [Related]
26. A phase II trial of accelerated multimodality therapy for locoregionally advanced cancer of the esophagus and gastroesophageal junction: the impact of clinical heterogeneity.
Adelstein DJ; Rice TW; Rybicki LA; Saxton JP; Videtic GM; Murthy SC; Zuccaro G; Vargo JJ; Dumot JA; Carroll MA
Am J Clin Oncol; 2007 Apr; 30(2):172-80. PubMed ID: 17414467
[TBL] [Abstract][Full Text] [Related]
27. Combined paclitaxel, cisplatin, and etoposide for patients with previously untreated esophageal and gastroesophageal carcinomas.
Lokich JJ; Sonneborn H; Anderson NR; Bern MM; Coco FV; Dow E; Oliynyk P
Cancer; 1999 Jun; 85(11):2347-51. PubMed ID: 10357404
[TBL] [Abstract][Full Text] [Related]
28. Dysphagia is not a Valuable Indicator of Tumor Response after Preoperative Chemotherapy for R0 Resected Patients with Adenocarcinoma of the Gastroesophageal Junction.
Strandby RB; Svendsen LB; Bæksgaard L; Egeland C; Achiam MP
Scand J Surg; 2016 Jun; 105(2):97-103. PubMed ID: 26250355
[TBL] [Abstract][Full Text] [Related]
29. Chemoradiotherapy of esophageal carcinoma.
Poplin EA; Khanuja PS; Kraut MJ; Herskovic AM; Lattin PB; Cummings G; Gaspar LE; Kinzie JL; Steiger Z; Vaitkevicius VK
Cancer; 1994 Aug; 74(4):1217-24. PubMed ID: 8055441
[TBL] [Abstract][Full Text] [Related]
30. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma.
Shah MA; Ramanathan RK; Ilson DH; Levnor A; D'Adamo D; O'Reilly E; Tse A; Trocola R; Schwartz L; Capanu M; Schwartz GK; Kelsen DP
J Clin Oncol; 2006 Nov; 24(33):5201-6. PubMed ID: 17114652
[TBL] [Abstract][Full Text] [Related]
31. A phase II study of perioperative concurrent chemotherapy, gefitinib, and hyperfractionated radiation followed by maintenance gefitinib in locoregionally advanced esophagus and gastroesophageal junction cancer.
Rodriguez CP; Adelstein DJ; Rice TW; Rybicki LA; Videtic GM; Saxton JP; Murthy SC; Mason DP; Ives DI
J Thorac Oncol; 2010 Feb; 5(2):229-35. PubMed ID: 20009775
[TBL] [Abstract][Full Text] [Related]
32. Phase 2 trial of preoperative irinotecan plus cisplatin and conformal radiotherapy, followed by surgery for esophageal cancer.
Knox JJ; Wong R; Visbal AL; Horgan AM; Guindi M; Hornby J; Xu W; Ringash J; Keshavjee S; Chen E; Haider M; Darling G
Cancer; 2010 Sep; 116(17):4023-32. PubMed ID: 20533506
[TBL] [Abstract][Full Text] [Related]
33. Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for esophagogastric adenocarcinoma: response, toxicity, quality of life, and survival.
Bamias A; Hill ME; Cunningham D; Norman AR; Ahmed FY; Webb A; Watson M; Hill AS; Nicolson MC; O'Brien ME; Evans TC; Nicolson V
Cancer; 1996 May; 77(10):1978-85. PubMed ID: 8640659
[TBL] [Abstract][Full Text] [Related]
34. A nationwide retrospective study of perioperative chemotherapy for gastroesophageal adenocarcinoma: tolerability, outcome, and prognostic factors.
Larsen AC; Holländer C; Duval L; Schønnemann K; Achiam M; Pfeiffer P; Yilmaz MK; Thorlacius-Ussing O; Bæksgaard L; Ladekarl M
Ann Surg Oncol; 2015 May; 22(5):1540-7. PubMed ID: 25348777
[TBL] [Abstract][Full Text] [Related]
35. Neoadjuvant radio-chemotherapy of adenocarcinoma of the oesophagogastric junction.
Samel S; Hofheinz R; Hundt A; Sturm J; Knoll MR; Wenz F; Queisser W; Post S
Onkologie; 2001 Jun; 24(3):278-82. PubMed ID: 11455222
[TBL] [Abstract][Full Text] [Related]
36. Pre-operative sequential chemo- and radiochemotherapy in locally advanced carcinomas of the lower oesophagus and gastro-oesophageal junction.
Stahl M; Vanhoefer U; Stuschke M; Walz MK; Müller C; Wilke H
Eur J Cancer; 1998 Apr; 34(5):668-73. PubMed ID: 9713272
[TBL] [Abstract][Full Text] [Related]
37. Phase II trial of weekly irinotecan/cisplatin in advanced esophageal cancer.
Ilson DH
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 14):22-5. PubMed ID: 15685830
[TBL] [Abstract][Full Text] [Related]
38. Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus.
Heath EI; Burtness BA; Heitmiller RF; Salem R; Kleinberg L; Knisely JP; Yang SC; Talamini MA; Kaufman HS; Canto MI; Topazian M; Wu TT; Olukayode K; Forastiere AA
J Clin Oncol; 2000 Feb; 18(4):868-76. PubMed ID: 10673530
[TBL] [Abstract][Full Text] [Related]
39. Neoadjuvant paclitaxel poliglumex, cisplatin, and radiation for esophageal cancer: a phase 2 trial.
Dipetrillo T; Suntharalingam M; Ng T; Fontaine J; Horiba N; Oldenburg N; Perez K; Birnbaum A; Battafarano R; Burrows W; Safran H
Am J Clin Oncol; 2012 Feb; 35(1):64-7. PubMed ID: 21297434
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of first-line systemic chemotherapy with epirubicin, cisplatin plus 5-fluorouracil and docetaxel, cisplatin plus 5-fluorouracil regimens in locally advanced inoperable or metastatic gastric or gastroesophageal junction adenocarcinoma: A prospective phase II study from South India.
Babu KG; Chaudhuri T; Lakshmaiah KC; Dasappa L; Jacob LA; Babu M; Rudresha AH; Lokesh KN; Rajeev LK
Indian J Cancer; 2017; 54(1):47-51. PubMed ID: 29199662
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]